Stocktoria
DBV Technologies S.A. DBVT
DBV Technologies S.A. (DBVT) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $5.6M at a -2607.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.663 |
| Retained earnings / assets | -1.682 |
| EBIT / assets | -0.629 |
| Equity / liabilities | 2.601 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DBVT | DBV Technologies S.A. | 3/9 | -2.63 | — | — |
| FATE | FATE THERAPEUTICS INC | 1/9 | -13.3 | — | -51.2% |
| OCGN | Ocugen, Inc. | 2/9 | — | — | — |
| CGON | CG Oncology, Inc. | 2/9 | — | — | — |
| CRSP | CRISPR Therapeutics AG | 1/9 | 6.42 | — | -90.6% |
| SRZN | Surrozen, Inc./DE | 2/9 | -15.54 | — | -67.4% |
| DYAI | DYADIC INTERNATIONAL INC | 1/9 | — | — | — |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
FAQ
Is DBVT financially healthy?
DBV Technologies S.A.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does DBVT pay a dividend?
No, DBV Technologies S.A. does not currently pay a dividend.
How profitable is DBVT?
In FY2025, DBV Technologies S.A. had a net margin of -2607.3% and a return on equity of -87.1%.
What is the analyst price target for DBVT?
The average Wall-Street price target for DBV Technologies S.A. is $39.84, about 181.8% above the recent price, from 6 analysts (consensus: buy).
Is DBVT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DBV Technologies S.A.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.